Neurobo Pharmaceuticals Stock Profit Margin
NRBODelisted Stock | USD 1.89 0.11 5.50% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
Neurobo |
Neurobo Pharmaceuticals Company Profit Margin Analysis
Neurobo Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Neurobo Pharmaceuticals has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
All Next | Launch Module |
Neurobo Fundamentals
Return On Equity | -1.61 | |||
Return On Asset | -0.74 | |||
Current Valuation | (1.18 M) | |||
Shares Outstanding | 8.62 M | |||
Shares Owned By Insiders | 65.23 % | |||
Shares Owned By Institutions | 12.71 % | |||
Number Of Shares Shorted | 34.27 K | |||
Price To Earning | (1.44) X | |||
Price To Book | 1.57 X | |||
Revenue | 7 K | |||
EBITDA | (15.88 M) | |||
Net Income | (12.47 M) | |||
Cash And Equivalents | 8.85 M | |||
Cash Per Share | 9.96 X | |||
Total Debt | 203 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 8.07 X | |||
Book Value Per Share | 1.50 X | |||
Cash Flow From Operations | (10.8 M) | |||
Short Ratio | 0.87 X | |||
Earnings Per Share | (4.29) X | |||
Target Price | 26.67 | |||
Beta | -0.28 | |||
Market Capitalization | 20.33 M | |||
Total Asset | 22.78 M | |||
Retained Earnings | (108.27 M) | |||
Working Capital | 16.55 M | |||
Current Asset | 21.62 M | |||
Current Liabilities | 11.75 M | |||
Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Neurobo Stock
0.81 | MMM | 3M Company | PairCorr |
0.71 | BA | Boeing | PairCorr |
0.67 | JPM | JPMorgan Chase | PairCorr |
0.67 | GE | GE Aerospace | PairCorr |
0.66 | CSCO | Cisco Systems | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |